Revvity Inc. (RVTY) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Revvity Inc. (RVTY) advanced +0.27% to $165.78 as options desks priced 55% call premium vs. 45% put protection around the $162 max-pain magnet. Solid 41% profit margin (3% return on capital), mixed timing at 77x P/E—hold if owned, no rush to chase.
WALTHAM, Mass., October 30, 2026--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 12, 2027 to all
Revvity has logged strong share gains in recent years, which naturally puts the spotlight on whether the current price lines up with the cash the business is expected to generate. With the stock near recent highs, the qu
Players: Labcorp, Quest Diagnostics, Eurofins Scientific, Exact Sciences and Revvity. The report profiles competitors, regional shares, segments, trends and opportunities.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Geneti
RVTY's Q3 earnings may gain from recovering pharma demand, stronger HCS demand and software growth, despite lingering spending and TB-related headwinds.
EW heads into Q3 with TAVR momentum, expanding mitral and tricuspid therapies and surgical heart growth. Can it beat earnings estimates?
VTRS, RVTY, ELAN and VCYT have earnings beat signals ahead of Q3 results. Can drug launches, lab spending and cancer tests overcome margin pressures?
GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disrup
Explore why the fund outperformed the Russell 2500 despite a 4.75% decline, with key winners, laggards, and performance insights.
NVST's Q3 earnings may have gained from Spark aligner growth, new product launches and improving margins. Can innovation drive another earnings beat?
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +3.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RVTY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RVTY. Explore sector supply chains on /butterfly.
Why RVTY Stock advanced +0.27% Today — RQD Quant Desk Flash. Solid 41% profit margin (3% return on capital), mixed timing at 77x P/E—hold if owned, no rush to chase.